Merck releases positive clinical trial data for Alzheimer’s disease drug candidate

July 16 2013 | By Márcio Barra

Merck released this Sunday results from a Phase Ib study of its experimental Alzheimer’s disease (AD) drug MK-8931, in patients with mild to moderate AD, with the drug achieving positive results in reducing the level of β amyloid proteins.

View original post 305 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s